"The personalized biotech revolution turns raw genetic information into tailored treatments that actually work for each patient, emphasizing the importance of data in developing effective therapies."
"Grand View Research pegs the global precision medicine market growing at a 16.3% compound annual growth rate till 2030 when it reaches $249.24 billion, indicating a robust future for the sector."
"Illumina doesn't sell therapies; it sells high-throughput sequencers and consumables that generate the genetic data everything else runs on, showcasing its foundational role in the biotech landscape."
"Cathie Wood has flagged genomics as a multi-decade megatrend, treating both sequencing and gene editing as essential infrastructure for personalized medicine, which is reflected in her investment strategy."
The precision medicine market is projected to grow significantly, reaching $249.24 billion by 2030. Key players include Illumina, which provides genomic sequencing technology, and CRISPR Therapeutics, known for gene editing. Cathie Wood has identified genomics as a long-term trend, emphasizing the importance of both sequencing and editing in developing personalized treatments. Her investment strategy reflects this, with significant holdings in both companies. Illumina reported a revenue increase, highlighting its role in generating critical genetic data for the industry.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]